These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1193 related items for PubMed ID: 18977553

  • 1. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 2. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K, Sasada T, Kawahara A, Hattori S, Kinoshita T, Takamori S, Ichiki M, Imamura Y, Ikeda J, Kage M, Kuwano M, Aizawa H.
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [Abstract] [Full Text] [Related]

  • 3. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
    Ikeda S, Takabe K, Suzuki K.
    Pathol Int; 2009 Dec; 59(12):863-7. PubMed ID: 20021611
    [Abstract] [Full Text] [Related]

  • 4. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.
    Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
    [Abstract] [Full Text] [Related]

  • 5. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
    Sève P, Isaac S, Trédan O, Souquet PJ, Pachéco Y, Pérol M, Lafanéchère L, Penet A, Peiller EL, Dumontet C.
    Clin Cancer Res; 2005 Aug 01; 11(15):5481-6. PubMed ID: 16061864
    [Abstract] [Full Text] [Related]

  • 6. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.
    Zhonghua Zhong Liu Za Zhi; 2009 Jan 01; 31(1):33-7. PubMed ID: 19538866
    [Abstract] [Full Text] [Related]

  • 7. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, Xiong Y, Wang D.
    Cancer Chemother Pharmacol; 2014 Oct 01; 74(4):777-86. PubMed ID: 25107571
    [Abstract] [Full Text] [Related]

  • 8. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.
    Cancer; 2008 Sep 15; 113(6):1379-86. PubMed ID: 18623378
    [Abstract] [Full Text] [Related]

  • 9. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
    Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW, Kim JH.
    Lung Cancer; 2008 Jun 15; 60(3):401-7. PubMed ID: 18036700
    [Abstract] [Full Text] [Related]

  • 10. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A, Sørensen JB.
    Lung Cancer; 2009 May 15; 64(2):131-9. PubMed ID: 18804893
    [Abstract] [Full Text] [Related]

  • 11. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M, Choi YD, Cho HJ, Ban HJ, Oh IJ, Kim KS, Song SY, Na KJ, Ahn SJ, Choi S, Kim YC.
    Respirology; 2012 Jan 15; 17(1):127-33. PubMed ID: 21899657
    [Abstract] [Full Text] [Related]

  • 12. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
    Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM, Zhou XW.
    Lung Cancer; 2012 Jul 15; 77(1):9-15. PubMed ID: 22306125
    [Abstract] [Full Text] [Related]

  • 13. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM, Tian C, Reed E.
    Cancer Res; 2007 May 01; 67(9):4474-81. PubMed ID: 17483363
    [Abstract] [Full Text] [Related]

  • 14. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
    Sève P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, Dabbagh L, Sawyer M, Dumontet C, Mackey JR.
    Cancer Chemother Pharmacol; 2007 Jun 01; 60(1):27-34. PubMed ID: 17021819
    [Abstract] [Full Text] [Related]

  • 15. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D.
    J Clin Oncol; 2007 Nov 20; 25(33):5172-9. PubMed ID: 18024864
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
    Edelman MJ, Schneider CP, Tsai CM, Kim HT, Quoix E, Luft AV, Kaleta R, Mukhopadhyay P, Trifan OC, Whitaker L, Reck M.
    J Clin Oncol; 2013 Jun 01; 31(16):1990-6. PubMed ID: 23589560
    [Abstract] [Full Text] [Related]

  • 17. [ERCC1 expression and outcomes of neo-adjuvant chemotherapy in elderly patients with non-small cell lung cancer].
    Li GF, Deng SJ, Weng WW, Guo G, Chen N.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Sep 01; 30(9):2131-3. PubMed ID: 20855270
    [Abstract] [Full Text] [Related]

  • 18. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
    Vilmar AC, Santoni-Rugiu E, Sørensen JB.
    Clin Cancer Res; 2011 Aug 01; 17(15):5205-14. PubMed ID: 21690572
    [Abstract] [Full Text] [Related]

  • 19. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ.
    J Clin Oncol; 2008 Jan 20; 26(3):468-73. PubMed ID: 18202422
    [Abstract] [Full Text] [Related]

  • 20. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA, Mountzios G, Soria JC.
    Curr Opin Pulm Med; 2007 Jul 20; 13(4):284-9. PubMed ID: 17534174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.